Drug Trial Radar · NCT06439082
A Study to Investigate the Efficacy and Safety of Crizanlizumab (5 mg/kg) Compared With Placebo in Adolescent and Adult Sickle Cell Disease Patients Who Experience Frequent Vaso-Occlusive Crises (SPARKLE)
Last checked: Nov 20, 2026Latest source record: Nov 10, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
354
Planned (sponsor's estimate)
Start
Oct 24, 2024
Primary completion
Jul 2, 2029
Study completion Jul 29, 2030
Sponsor
- Lead sponsor
- Novartis PharmaceuticalsNovartis (NVS)
- Sponsor type
- Industry
- First posted
- Jun 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 12 years, up to 100 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase III, multi-center, randomized, placebo-controlled, double-blind study to assess efficacy and safety of crizanlizumab (5 mg/kg) versus placebo, with or without hydroxyurea/hydroxycarbamide therapy, in adolescent and adult Sickle Cell Disease patients with frequent vaso-occlusive crises.
Conditions
- Sickle Cell Disease
Interventions
CrizanlizumabBiological
Crizanlizumab is supplied in single use 10 mL glass vials at a concentration of 10 mg/mL. One vial contains 100 mg of crizanlizumab. This is a concentrate for solution for IV infusion.
PlaceboDrug
Placebo is supplied in single use 10 mL glass vials at a concentration of 0 mg/mL. This is a concentrate for solution for IV infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Annualized rate of VOCs that are healthcare professional (HCP)-managed (including VOCs leading to management at a health care facility or those managed via remote consultation) in each treatment armTime frame: 1 year
Locations
36 sites in 5 countries. Site status is shown where the registry gives one.
University Of Alabama
Birmingham, Alabama · Recruiting
Ctr for Inherited Blood Disorders
Orange, California · Recruiting
Childrens National Hospital
Washington D.C., District of Columbia · Recruiting
University of Florida
Jacksonville, Florida · Recruiting
Augusta University Georgia
Augusta, Georgia · Recruiting
WCG Sonar Clinical Research
Riverdale, Georgia · Recruiting
Uni of Illinois Hospital and HSC
Chicago, Illinois · Recruiting
Norton Children s Hospital
Louisville, Kentucky · Recruiting
The Johns Hopkins University School of Medicine
Baltimore, Maryland · Recruiting
Southern Specialty Research
Flowood, Mississippi · Recruiting
Childrens Hospital at Montefiore
The Bronx, New York · Recruiting
East Carolina University
Greenville, North Carolina · Recruiting
Wake Forest University Baptist Medical Center
Winston-Salem, North Carolina · Recruiting
Spoknwrdclinicaltrials
Easton, Pennsylvania · Withdrawn
Thomas Jefferson University Me
Philadelphia, Pennsylvania · Recruiting
Texas Childrens Cancer and Hematology Center
Houston, Texas · Recruiting
U of TX Health Science Ct
Houston, Texas · Recruiting
Novartis Investigative Site
Salvador, Estado de Bahia, Brazil · Recruiting
Novartis Investigative Site
São Luís, Maranhão, Brazil · Recruiting
Novartis Investigative Site
Campinas, São Paulo, Brazil · Recruiting
Novartis Investigative Site
Ribeirão Preto, São Paulo, Brazil · Recruiting
Novartis Investigative Site
Sao Jose Rio Preto, São Paulo, Brazil · Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Recruiting
Novartis Investigative Site
São Paulo, São Paulo, Brazil · Recruiting
Novartis Investigative Site
Montería, Colombia · Recruiting
Novartis Investigative Site
Medellín, Antioquia, Colombia · Recruiting
Novartis Investigative Site
Cali, Valle del Cauca Department, Colombia · Recruiting
Novartis Investigative Site
Cali, Valle del Cauca Department, Colombia · Recruiting
Novartis Investigative Site
Eldoret, Kenya · Recruiting
Novartis Investigative Site
Kisumu, Kenya · Recruiting
Novartis Investigative Site
Kisumu, Kenya · Recruiting
Novartis Investigative Site
Siaya, Kenya · Recruiting
Novartis Investigative Site
Ahero, Kisumu County, Kenya · Recruiting
Novartis Investigative Site
Kampala, Uganda · Recruiting
Novartis Investigative Site
Masaka, Uganda · Recruiting
Novartis Investigative Site
Tororo, Uganda · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.